Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of combined Qilin pill and estradiol valerate tablets on irregular menstruation in patients, and their serum levels of estradiol, progesterone and luteinizing hormone
Abstract
Purpose: To determine the clinical effect of combined treatment with Qilin pill and estradiol valerate tablets on irregular menstruation patients, and its impact on serum levels of estradiol (E2), progesterone (P) and luteinizing hormone (LH).
Methods: A total of 120 irregular menstruation patients admitted to our hospital from January 2019 to January 2020 were randomly divided into group A (n=60) and group B (n = 60). Group B was treated with estradiol valerate tablets only, while group A was given Qilin pill, in addition to estradiol tablets. Treatment effectiveness, time taken to achieve normal menstruation, ovulation rate, hormonal levels, endometrial thickness, and clinical symptom scores were compared between the two groups of patients.
Results: There was higher treatment effectiveness in group A than in group B (p <0.05). The time taken to return to normal menstruation was significantly shorter in group A than in group B (p < 0.001). Group A patients had markedly higher ovulation rate, higher endometrial thickness, and more favorable hormonal levels than patients in group B (p < 0.05). Moreover, post-treatment clinical symptom score of group A was superior to that of group B (p <0.001).
Conclusion: The combined use of Qilin pills and estradiol valerate tablets mitigates clinical symptoms in patients with irregular menstruation, increases their ovulation rate and hormonal levels, and enhances return to normal menstruation. Therefore, the combination treatment appears to be suitable for the management of menstrual issues.
